A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01589159|
Recruitment Status : Completed
First Posted : May 1, 2012
Last Update Posted : February 27, 2017
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Breast Cancer||Drug: Capecitabine Drug: Etoposide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||54 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase Ⅱ Study of an All-Oral Combination of Low-dose Etoposide/Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and/or Taxanes|
|Actual Study Start Date :||January 2013|
|Actual Primary Completion Date :||July 2016|
|Actual Study Completion Date :||December 2016|
Drug:capecitabine 700mg/m2, twice daily on days 1-14.Drug: Etoposide
Etoposide 30mg/m2, once daily on days 1-7.
- Clinical benefit rate [ Time Frame: 24 weeks after the treatment ]Clinical benefit is defined as CR, PR, SD≥24 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01589159
|Peking University Cancer Hospital & Institute|
|Beijing, Beijing, China, 100142|
|Study Chair:||Yan Wei, Doctor||Peking University Cancer Hospital & Institute|